1. Home
  2. VNDA
  3. VNDA News

Latest Vanda Pharmaceuticals Inc. (VNDA) News on March 31, 2025

Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia
VNDA

PR Newswire

4 hours ago

Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia

VNDA

Argus Research

5 hours ago

Daily – Vickers Top Insider Picks for 03/31/2025

VNDA

Argus Research

3 days ago

Daily – Vickers Top Insider Picks for 03/28/2025

VNDA

Argus Research

4 days ago

Daily – Vickers Top Insider Picks for 03/27/2025

VNDA

Argus Research

5 days ago

Daily – Vickers Top Insider Picks for 03/26/2025

VNDA

Argus Research

6 days ago

Daily – Vickers Top Insider Picks for 03/25/2025

VNDA

Argus Research

7 days ago

Daily – Vickers Top Insider Picks for 03/24/2025

VNDA

Argus Research

10 days ago

Daily – Vickers Top Insider Picks for 03/21/2025

VNDA

Argus Research

11 days ago

Daily – Vickers Top Insider Picks for 03/20/2025

VNDA

Argus Research

12 days ago

Daily – Vickers Top Insider Picks for 03/19/2025

VNDA

Argus Research

13 days ago

Daily – Vickers Top Insider Picks for 03/18/2025

VNDA

MT Newswires

14 days ago

Vanda Raises Concerns Over FDA Review Timeline for Motion Sickness Therapy Candidate

VNDA

Argus Research

14 days ago

Daily – Vickers Top Insider Picks for 03/17/2025

VNDA

Argus Research

17 days ago

Daily – Vickers Top Insider Picks for 03/14/2025

VNDA

Argus Research

18 days ago

Daily – Vickers Top Insider Picks for 03/13/2025

VNDA

Argus Research

19 days ago

Daily – Vickers Top Insider Picks for 03/12/2025

VNDA

Argus Research

20 days ago

Daily – Vickers Top Insider Picks for 03/11/2025

VNDA

Argus Research

21 days ago

Daily – Vickers Top Insider Picks for 03/10/2025

VNDA

Argus Research

24 days ago

Daily – Vickers Top Insider Picks for 03/07/2025

VNDA

Argus Research

25 days ago

Daily – Vickers Top Insider Picks for 03/06/2025

VNDA

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 03/05/2025

VNDA

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 03/03/2025

US High Growth Tech Stocks With Strong Potential
VNDA

Simply Wall St.

a month ago

US High Growth Tech Stocks With Strong Potential

February 2025 Penny Stocks To Keep An Eye On
VNDA

Simply Wall St.

a month ago

February 2025 Penny Stocks To Keep An Eye On

Vanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S"
VNDA

PR Newswire

a month ago

Vanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S"

VNDA

Thomson Reuters StreetEvents

a month ago

Q4 2024 Vanda Pharmaceuticals Inc Earnings Call

Vanda Pharmaceuticals Inc (VNDA) Q4 2024 Earnings Call Highlights: Revenue Growth Amidst Challenges
VNDA

GuruFocus.com

a month ago

Vanda Pharmaceuticals Inc (VNDA) Q4 2024 Earnings Call Highlights: Revenue Growth Amidst Challenges

Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Tops Revenue Estimates
VNDA

Zacks

2 months ago

Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Tops Revenue Estimates

VNDA

Associated Press Finance

2 months ago

Vanda: Q4 Earnings Snapshot

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
VNDA

PR Newswire

2 months ago

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025
VNDA

PR Newswire

2 months ago

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

Vanda and AnaptysBio link for generalised pustular psoriasis therapy
VNDA

Pharmaceutical Technology

2 months ago

Vanda and AnaptysBio link for generalised pustular psoriasis therapy

VNDA

MT Newswires

2 months ago

Vanda Pharmaceuticals, AnaptysBio Sign Global License Agreement for Imsidolimab

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
VNDA

GlobeNewswire

2 months ago

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

BioAge drops obesity drug; Akero, 89bio cash in on MASH data
VNDA

BioPharma Dive

2 months ago

BioAge drops obesity drug; Akero, 89bio cash in on MASH data

US Exchange Penny Stocks To Watch In January 2025
VNDA

Simply Wall St.

2 months ago

US Exchange Penny Stocks To Watch In January 2025

Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis
VNDA

PR Newswire

2 months ago

Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis

FDA Unveils Grounds For Rejecting Vanda Pharmaceuticals Stomach Paralysis Candidate
VNDA

Benzinga

2 months ago

FDA Unveils Grounds For Rejecting Vanda Pharmaceuticals Stomach Paralysis Candidate

VNDA

MT Newswires

3 months ago

Vanda Pharmaceuticals Highlights Issues in Gastroparesis Treatment Application Review in Letter to FDA Commissioner

Vanda's Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review
VNDA

PR Newswire

3 months ago

Vanda's Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review

Is it a Good Idea to Invest in Vanda Pharmaceuticals Stock Now?
VNDA

Zacks

3 months ago

Is it a Good Idea to Invest in Vanda Pharmaceuticals Stock Now?

KOD Stock Rallies 271% in 6 Months on Eye Disease Program Updates
VNDA

Zacks

3 months ago

KOD Stock Rallies 271% in 6 Months on Eye Disease Program Updates

3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying
VNDA

Zacks

3 months ago

3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying

VNDA

MT Newswires

3 months ago

Vanda Pharmaceuticals' Prospective Treatment for Blood Cancer Receives US FDA's Orphan Drug Designation

Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera
VNDA

PR Newswire

3 months ago

Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera

Exploring Three High Growth Tech Stocks In The United States
VNDA

Simply Wall St.

3 months ago

Exploring Three High Growth Tech Stocks In The United States

US Penny Stocks To Watch In December 2024
VNDA

Simply Wall St.

3 months ago

US Penny Stocks To Watch In December 2024

New Strong Buy Stocks for November 14th
VNDA

Zacks

5 months ago

New Strong Buy Stocks for November 14th

Vanda Pharmaceuticals Announces Participation at November 2024 Investor Conferences
VNDA

PR Newswire

5 months ago

Vanda Pharmaceuticals Announces Participation at November 2024 Investor Conferences

Vanda Pharmaceuticals Inc (VNDA) Q3 2024 Earnings Call Highlights: Revenue Surge Amidst Rising ...
VNDA

GuruFocus.com

5 months ago

Vanda Pharmaceuticals Inc (VNDA) Q3 2024 Earnings Call Highlights: Revenue Surge Amidst Rising ...

VNDA

Associated Press Finance

5 months ago

Vanda: Q3 Earnings Snapshot

Vanda Pharmaceuticals Reports Third Quarter 2024 Financial Results
VNDA

PR Newswire

5 months ago

Vanda Pharmaceuticals Reports Third Quarter 2024 Financial Results

Vanda Pharmaceuticals Leads The Pack Of 3 US Penny Stocks
VNDA

Simply Wall St.

5 months ago

Vanda Pharmaceuticals Leads The Pack Of 3 US Penny Stocks

Over 200% Stock Upside - Vanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst
VNDA

Benzinga

5 months ago

Over 200% Stock Upside - Vanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst

Health Care Roundup: Market Talk
VNDA

The Wall Street Journal

5 months ago

Health Care Roundup: Market Talk

Vanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024
VNDA

PR Newswire

5 months ago

Vanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024

Biotech Stock Roundup: VNDA, JAZZ Up on Updates, NVAX Suffers Setback & More
VNDA

Zacks

5 months ago

Biotech Stock Roundup: VNDA, JAZZ Up on Updates, NVAX Suffers Setback & More

VNDA Rejects Second Takeover Bid by Cycle Group, Stock Rises
VNDA

Zacks

6 months ago

VNDA Rejects Second Takeover Bid by Cycle Group, Stock Rises

Cycle Pharmaceuticals reaffirms proposal to acquire Vanda Pharmaceuticals
VNDA

TipRanks

6 months ago

Cycle Pharmaceuticals reaffirms proposal to acquire Vanda Pharmaceuticals

VNDA

MT Newswires

6 months ago

Vanda Pharmaceuticals Shares Rise; Cycle Pharmaceuticals' Buyout Offer Rejected Again

Vanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group Holdings Ltd.
VNDA

PR Newswire

6 months ago

Vanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group Holdings Ltd.

Vanda Pharmaceuticals rejects Cycle Pharma's second takeover offer
VNDA

Reuters

6 months ago

Vanda Pharmaceuticals rejects Cycle Pharma's second takeover offer

Cycle Pharma Is Said to Stand By $488 Million Offer for Vanda
VNDA

Bloomberg

6 months ago

Cycle Pharma Is Said to Stand By $488 Million Offer for Vanda

Biotech Stock Roundup: BHVN, WVE, ZVRA Stocks Up on Updates, BIIB & UCBs Study Data & More
VNDA

Zacks

6 months ago

Biotech Stock Roundup: BHVN, WVE, ZVRA Stocks Up on Updates, BIIB & UCBs Study Data & More

VNDA Stock Down as FDA Rejects NDA for Tradipitant in Gastroparesis
VNDA

Zacks

6 months ago

VNDA Stock Down as FDA Rejects NDA for Tradipitant in Gastroparesis

Novo sinks on obesity drug results; Sanofi reveals anticipated MS data
VNDA

BioPharma Dive

6 months ago

Novo sinks on obesity drug results; Sanofi reveals anticipated MS data

FDA declines approval of Vanda’s gastroparesis treatment
VNDA

Pharmaceutical Technology

6 months ago

FDA declines approval of Vanda’s gastroparesis treatment

Why Vanda Pharmaceuticals Stock Sank by Nearly 6% Today
VNDA

Motley Fool

6 months ago

Why Vanda Pharmaceuticals Stock Sank by Nearly 6% Today

VNDA

MT Newswires

6 months ago

Vanda Pharma Shares Fall 15% as FDA Denies Approval of Tradipitant NDA for Treating Gastroparesis Symptoms

FDA Declines to Approve Vanda's Marketing Application for Tradipitant in Gastroparesis
VNDA

PR Newswire

6 months ago

FDA Declines to Approve Vanda's Marketing Application for Tradipitant in Gastroparesis

Vanda Pharmaceuticals Announces Participation in the 2024 Cantor Global Healthcare Conference
VNDA

PR Newswire

7 months ago

Vanda Pharmaceuticals Announces Participation in the 2024 Cantor Global Healthcare Conference

Vanda Pharmaceuticals Announces Participation in the H.C. Wainwright Global Investment Conference
VNDA

PR Newswire

7 months ago

Vanda Pharmaceuticals Announces Participation in the H.C. Wainwright Global Investment Conference

Vanda Pharmaceuticals Announces Participation in the Wells Fargo 2024 Healthcare Conference
VNDA

PR Newswire

7 months ago

Vanda Pharmaceuticals Announces Participation in the Wells Fargo 2024 Healthcare Conference

VNDA

Thomson Reuters StreetEvents

8 months ago

Q2 2024 Vanda Pharmaceuticals Inc Earnings Call

VNDA

Associated Press Finance

8 months ago

Vanda: Q2 Earnings Snapshot

Vanda Pharmaceuticals Reports Second Quarter 2024 Financial Results
VNDA

PR Newswire

8 months ago

Vanda Pharmaceuticals Reports Second Quarter 2024 Financial Results

Vanda Pharmaceuticals to Announce Second Quarter 2024 Financial Results on July 31, 2024
VNDA

PR Newswire

8 months ago

Vanda Pharmaceuticals to Announce Second Quarter 2024 Financial Results on July 31, 2024

VNDA

MT Newswires

9 months ago

Vanda Pharmaceuticals Says Federal Court Allows Patent Lawsuit Over Hetlioz

Federal Court Allows Vanda's HETLIOZ® Patent Lawsuit to Proceed against Teva and Apotex
VNDA

PR Newswire

9 months ago

Federal Court Allows Vanda's HETLIOZ® Patent Lawsuit to Proceed against Teva and Apotex

Jazz drug for tremor fails study; Radiopharma drug developer ITM swaps CEOs
VNDA

BioPharma Dive

9 months ago

Jazz drug for tremor fails study; Radiopharma drug developer ITM swaps CEOs

Vanda Pharmaceuticals Board of Directors Determines that Recent Unsolicited Takeover Proposals Are Not in the Best Interests of the Company and its Shareholders
VNDA

PR Newswire

9 months ago

Vanda Pharmaceuticals Board of Directors Determines that Recent Unsolicited Takeover Proposals Are Not in the Best Interests of the Company and its Shareholders

VNDA

MT Newswires

10 months ago

Sector Update: Health Care Stocks Ease Late Afternoon

VNDA

MT Newswires

10 months ago

Sector Update: Health Care Stocks Softer Thursday Afternoon

VNDA

MT Newswires

10 months ago

Sector Update: Health Care

VNDA

MT Newswires

10 months ago

Vanda Pharmaceuticals Receives Revised Offer From Future Pak; Shares Rise

Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak
VNDA

PR Newswire

10 months ago

Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak

Cycle Pharmaceuticals offers to acquire Vanda Pharma for $466m
VNDA

Pharmaceutical Technology

10 months ago

Cycle Pharmaceuticals offers to acquire Vanda Pharma for $466m

Vanda (VNDA) Surges 24.2%: Is This an Indication of Further Gains?
VNDA

Zacks

10 months ago

Vanda (VNDA) Surges 24.2%: Is This an Indication of Further Gains?

VNDA

MT Newswires

10 months ago

Sector Update: Health Care Stocks Higher in Late Afternoon Trading

VNDA

MT Newswires

10 months ago

Sector Update: Health Care Stocks Advance Thursday Afternoon

VNDA

MT Newswires

10 months ago

Sector Update: Health Care

VNDA

MT Newswires

10 months ago

Vanda Pharmaceuticals' Shares Rally After Company Receives $466 Million Buyout Offer From Cycle Pharma

Vanda Pharmaceuticals Confirms Receipt of Unsolicited, Non-Binding Indication of Interest from Cycle Group Holdings Ltd.
VNDA

PR Newswire

10 months ago

Vanda Pharmaceuticals Confirms Receipt of Unsolicited, Non-Binding Indication of Interest from Cycle Group Holdings Ltd.

VNDA

MT Newswires

10 months ago

Cycle Pharmaceuticals Offers to Buy Vanda Pharmaceuticals for $466 Million

VNDA

MT Newswires

10 months ago

Top Premarket Gainers

VNDA

MT Newswires

10 months ago

Vanda Pharmaceuticals to Commercialize Treatment of Multiple Sclerosis in the US

Vanda Pharmaceuticals Announces Participation in the Jefferies 2024 Global Healthcare Conference
VNDA

PR Newswire

10 months ago

Vanda Pharmaceuticals Announces Participation in the Jefferies 2024 Global Healthcare Conference

Vanda Pharmaceuticals Announces Completion of Transfer of FDA Marketing Authorization for PONVORY®
VNDA

PR Newswire

10 months ago

Vanda Pharmaceuticals Announces Completion of Transfer of FDA Marketing Authorization for PONVORY®

Vanda Pharmaceuticals Announces Presentations at SLEEP 2024
VNDA

PR Newswire

10 months ago

Vanda Pharmaceuticals Announces Presentations at SLEEP 2024

Vanda Pharmaceuticals Board of Directors Determines that Revised Unsolicited Takeover Proposal is Not in the Best Interests of the Company and its Shareholders
VNDA

PR Newswire

10 months ago

Vanda Pharmaceuticals Board of Directors Determines that Revised Unsolicited Takeover Proposal is Not in the Best Interests of the Company and its Shareholders

Share on Social Networks: